Sarah Asad1, Carlos H Barcenas2, Richard J Bleicher3, Adam L Cohen4, Sara H Javid5, Ellis G Levine6, Nancy U Lin7, Beverly Moy8, Joyce Niland9, Antonio C Wolff10, Michael J Hassett7, Daniel G Stover1. 1. Ohio State University Wexner Medical Center, Columbus, Ohio. 2. MD Anderson Cancer Center, Houston, Texas. 3. Fox Chase Cancer Center, Philadelphia, Pennsylvania. 4. University of Utah, Salt Lake City, Utah. 5. Seattle Cancer Care Alliance, Seattle, Washington. 6. Roswell Park Comprehensive Cancer Center, Buffalo, New York. 7. Dana-Farber Cancer Institute, and. 8. Massachusetts General Hospital, Boston, Massachusetts. 9. City of Hope National Medical Center, Duarte, California; and. 10. Johns Hopkins University, Baltimore, Maryland.
Abstract
BACKGROUND: Triple-negative breast cancer (TNBC) accounts for disproportionately poor outcomes in breast cancer, driven by a subset of rapid-relapse TNBC (rrTNBC) with marked chemoresistance, rapid metastatic spread, and poor survival. Our objective was to evaluate clinicopathologic and sociodemographic features associated with rrTNBC. METHODS: We included patients diagnosed with stage I-III TNBC in 1996 through 2012 who received chemotherapy at 1 of 10 academic cancer centers. rrTNBC was defined as a distant metastatic recurrence event or death ≤24 months after diagnosis. Features associated with rrTNBC were included in a multivariable logistic model upon which backward elimination was performed with a P<.10 criterion, with a final multivariable model applied to training (70%) and independent validation (30%) cohorts. RESULTS: Among all patients with breast cancer treated at these centers, 3,016 fit the inclusion criteria. Training cohort (n=2,112) bivariable analyses identified disease stage, insurance type, age, body mass index, race, and income as being associated with rrTNBC (P<.10). In the final multivariable model, rrTNBC was significantly associated with higher disease stage (adjusted odds ratio for stage III vs I, 16.0; 95% CI, 9.8-26.2; P<.0001), Medicaid/indigent insurance, lower income (by 2000 US Census tract), and younger age at diagnosis. Model performance was consistent between the training and validation cohorts. In sensitivity analyses, insurance type, low income, and young age were associated with rrTNBC among patients with stage I/II but not stage III disease. When comparing rrTNBC versus late relapse (>24 months), we found that insurance type and young age remained significant. CONCLUSIONS: Timing of relapse in TNBC is associated with stage of disease and distinct sociodemographic features, including insurance type, income, and age at diagnosis.
BACKGROUND: Triple-negative breast cancer (TNBC) accounts for disproportionately poor outcomes in breast cancer, driven by a subset of rapid-relapse TNBC (rrTNBC) with marked chemoresistance, rapid metastatic spread, and poor survival. Our objective was to evaluate clinicopathologic and sociodemographic features associated with rrTNBC. METHODS: We included patients diagnosed with stage I-III TNBC in 1996 through 2012 who received chemotherapy at 1 of 10 academic cancer centers. rrTNBC was defined as a distant metastatic recurrence event or death ≤24 months after diagnosis. Features associated with rrTNBC were included in a multivariable logistic model upon which backward elimination was performed with a P<.10 criterion, with a final multivariable model applied to training (70%) and independent validation (30%) cohorts. RESULTS: Among all patients with breast cancer treated at these centers, 3,016 fit the inclusion criteria. Training cohort (n=2,112) bivariable analyses identified disease stage, insurance type, age, body mass index, race, and income as being associated with rrTNBC (P<.10). In the final multivariable model, rrTNBC was significantly associated with higher disease stage (adjusted odds ratio for stage III vs I, 16.0; 95% CI, 9.8-26.2; P<.0001), Medicaid/indigent insurance, lower income (by 2000 US Census tract), and younger age at diagnosis. Model performance was consistent between the training and validation cohorts. In sensitivity analyses, insurance type, low income, and young age were associated with rrTNBC among patients with stage I/II but not stage III disease. When comparing rrTNBC versus late relapse (>24 months), we found that insurance type and young age remained significant. CONCLUSIONS: Timing of relapse in TNBC is associated with stage of disease and distinct sociodemographic features, including insurance type, income, and age at diagnosis.
Authors: Rebecca Dent; Maureen Trudeau; Kathleen I Pritchard; Wedad M Hanna; Harriet K Kahn; Carol A Sawka; Lavina A Lickley; Ellen Rawlinson; Ping Sun; Steven A Narod Journal: Clin Cancer Res Date: 2007-08-01 Impact factor: 12.531
Authors: A M Brewster; C Etzel; R Zhou; Y Wong; S Edge; D W Blayney; J Wilson; C Hudis; R Ottesen; M E Hughes; J C Weeks; R L Theriault Journal: Breast Cancer Res Treat Date: 2011-08-02 Impact factor: 4.872
Authors: Nicholas Navin; Jude Kendall; Jennifer Troge; Peter Andrews; Linda Rodgers; Jeanne McIndoo; Kerry Cook; Asya Stepansky; Dan Levy; Diane Esposito; Lakshmi Muthuswamy; Alex Krasnitz; W Richard McCombie; James Hicks; Michael Wigler Journal: Nature Date: 2011-03-13 Impact factor: 49.962
Authors: Paula M Lantz; Mahasin Mujahid; Kendra Schwartz; Nancy K Janz; Angela Fagerlin; Barbara Salem; Lihua Liu; Dennis Deapen; Steven J Katz Journal: Am J Public Health Date: 2006-10-31 Impact factor: 9.308
Authors: Daniel G Stover; Jonathan L Coloff; William T Barry; Joan S Brugge; Eric P Winer; Laura M Selfors Journal: Clin Cancer Res Date: 2016-06-21 Impact factor: 12.531
Authors: Sam Harper; John Lynch; Stephen C Meersman; Nancy Breen; William W Davis; Marsha C Reichman Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-01 Impact factor: 4.254
Authors: Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens Journal: N Engl J Med Date: 2018-10-20 Impact factor: 91.245
Authors: Jonathan L Vandergrift; Joyce C Niland; Richard L Theriault; Stephen B Edge; Yu-Ning Wong; Loretta S Loftus; Tara M Breslin; Clifford A Hudis; Sara H Javid; Hope S Rugo; Samuel M Silver; Eva M Lepisto; Jane C Weeks Journal: J Natl Cancer Inst Date: 2012-12-21 Impact factor: 13.506
Authors: Ines Vaz-Luis; Rebecca A Ottesen; Melissa E Hughes; Rizvan Mamet; Harold J Burstein; Stephen B Edge; Ana M Gonzalez-Angulo; Beverly Moy; Hope S Rugo; Richard L Theriault; Jane C Weeks; Eric P Winer; Nancy U Lin Journal: J Clin Oncol Date: 2014-06-02 Impact factor: 44.544
Authors: Samilia Obeng-Gyasi; Sarah Asad; James L Fisher; Saurabh Rahurkar; Daniel G Stover Journal: Ann Surg Oncol Date: 2021-02-14 Impact factor: 4.339